What does CUSIP 47103J105 represent in this 13F holders report?

CUSIP 47103J105 is the security identifier for JANX - Janux Therapeutics, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held JANX - Janux Therapeutics, Inc. - Common Stock in Q1 2022?

46 institutional investors reported JANX - Janux Therapeutics, Inc. - Common Stock for Q1 2022. Use the holders table for investor-level position and value details.

Janux Therapeutics, Inc. - Common Stock (JANX)

CUSIP: 47103J105

Q1 2022 13F Holders as of 31 Mar 2022

Security type / class: Equity / Common Stock
Total 13F shares: 28,388,419
Total 13F value: $407,113,023
Share change: +889,545
SEC-reported price per share: $14.34
Number of holders: 46
Value change: +$11,406,319
Number of buys: 26
Number of sells: 14
Shares outstanding: 61,171,000

Security key

47103J105

Report period

Q1 2022

Institutions

Top holders

JANX full security history Ownership snapshot Full 13F holder table Janux Therapeutics, Inc. SEC filings Janux Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of JANX - Janux Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

RA CAPITAL MANAGEMENT, L.P.

Disclosed value leader

RA CAPITAL MANAGEMENT, L.P.

Comparable rows

15/15

Latest evidence

31 Dec 2021

13F 3/4/5 Lead comparable stake: 14% Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 14%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.

Comparable ownership Top 5

RA CAPITAL MANAGEMENT, L.P. 14%

FMR LLC 8.2%

ORBIMED ADVISORS LLC 4.6%

Janus Henderson Group Ltd. 3.9%

CITADEL ADVISORS LLC 3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
RA CAPITAL MANAGEMENT, L.P.	13F Company 13F	14%	$171,072,000 8,670,644 shares	—	31 Dec 2021
FMR LLC	13F Company 13F	8.2%	$98,480,000 4,991,402 shares	—	31 Dec 2021
ORBIMED ADVISORS LLC	13F 3/4/5 Company · Director 13F 3/4/5	4.6%	$55,962,000 2,836,386 shares	—	31 Dec 2021
Janus Henderson Group Ltd.	13F Company 13F	3.9%	$46,558,000 2,400,893 shares	—	31 Dec 2021
CITADEL ADVISORS LLC	13F Company 13F	3%	$36,568,000 1,853,432 shares	—	31 Dec 2021
EcoR1 Capital, LLC	13F Company 13F	2.3%	$27,858,000 1,411,975 shares	—	31 Dec 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

28,388,419

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2022 vs Q1 2022 Across Filers

Q1 2022 holders

Holder diff

Investor	Q1 2022 Shares	Q1 2022 Shares	Share Diff	Share Chg %	Q1 2022 value	Q1 2022 value	Value change	Value Chg %